摘要
目的探讨度拉糖肽对2型糖尿病(T2DM)合并非酒精性脂肪性肝病(NAFLD)的疗效及安全性。方法选取2019年7~10月成都市第二人民医院住院部收治的50例初诊T2DM合并NAFLD的患者,给予度拉糖肽治疗12周,观察治疗前后患者的空腹血糖(FPG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbA1c)、体质量指数(BMI)、甘油三酯(TG)、胆固醇(TC)、谷丙转氨酶(ALT)、谷草转氨酶(AST)、谷氨酰转肽酶(GGT)等指标及肝脏彩超的变化,并分析脂肪肝的治疗效果及安全性。结果患者治疗前与治疗12周后的FPG[(9.50±0.86)mmol/L vs(5.74±0.68)mmol/L]、2 hPG[(15.68±1.96)mmol/L vs(8.36±1.69)mmol/L]、HbA1c[(9.15±0.67)%vs(6.81±0.78)%]、BMI[(26.45±1.42)kg/m^2 vs(23.35±1.01)kg/m^2]、TC[(5.40±0.93)mmol/L vs(3.46±0.87)mmol/L]、TG[(4.89±0.25)mmol/L vs(2.19±0.58)mmol/L]、ALT[(66.02±11.73)U/L vs(44.24±11.43)U/L]、AST[(61.64±13.18)U/L vs(36.72±9.94)U/L]、GGT[(68.64±10.20)U/L vs(31.78±10.09)U/L]比较,治疗12周后较治疗前明显降低,差异均有显著统计学意义(P<0.01);脂肪肝治疗总有效率为72.0%,总不良反应发生率为8.0%。结论度拉糖肽能明显改善T2DM合并NAFLD患者的血糖、血脂、BMI、肝脏功能等指标,脂肪肝疗效显著且安全性良好。
Objective To investigate the clinical efficacy and safety of dulaglutide on type 2 diabetes mellitus(T2DM)complicated with non-alcoholic fatty liver disease(NAFLD).Methods Fifty inpatients with new-onset T2DM complicated with NAFLD admitted to Chengdu Second People’s Hospital from July 2019 to October 2019 were selected and given dulaglutide treatment for 12 weeks.Fasting plasma glucose(FPG),2 h postprandial blood glucose(2 hPG),glycosylated hemoglobin(HbA1c),body mass index(BMI),triglyceride(TG),cholesterol(TC),alanine aminotransferase(ALT),aspartate aminotransferase(AST),gamma-glutamyl transpeptidase(GGT)were compared before and after the treatment,and fat content of liver were assessed by abdominal ultrasound.Additionally,the total effective rate and safety were analyzed.Results After treatment,FPG,2 hPG,HbA1c,BMI,TC,TG,ALT,AST,GGT were significantly decreased compared with those before treatment(P<0.01):FPG,(9.50±0.86)mmol/L vs(5.74±0.68)mmol/L;2 hPG,(15.68±1.96)mmol/L vs(8.36±1.69)mmol/L;HbA1c,(9.15±0.67)%vs(6.81±0.78)%;BMI,(26.45±1.42)kg/m^2 vs(23.35±1.01)kg/m^2;TC,(5.40±0.93)mmol/L vs(3.46±0.87)mmol/L;TG,(4.89±0.25)mmol/L vs(2.19±0.58)mmol/L;ALT,(66.02±11.73)U/L vs(44.24±11.43)U/L;AST,(61.64±13.18)U/L vs(36.72±9.94)U/L;GGT,(68.64±10.20)U/L vs(31.78±10.09)U/L.Additionally,the total effective rate was 72.0%,and the incidences of adverse effect was 8.0%.Conclusion Dulaglutide therapy is safe and effective in the treatment of patients with T2DM complicated with NAFLD,which can significantly improve the blood glucose,blood lipid,BMI,liver function.
作者
张文龙
叶鹏
郑莉
魏东
ZHANG Wen-long;YE Peng;ZHENG Li;WEI Dong(Department of Endocrinology and Metabolism,Chengdu Second People’s Hospital,Chengdu 610021,Sichuan,CHINA)
出处
《海南医学》
CAS
2020年第17期2243-2245,共3页
Hainan Medical Journal
关键词
2型糖尿病
非酒精性脂肪性肝病
度拉糖肽
糖脂代谢
疗效
不良反应
Type 2 diabetes mellitus
Non-alcoholic fatty liver disease
Dulaglutide
Glucolipid metabolism
Clinical efficacy
Adverse effect
